Literature DB >> 22847263

Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia.

Lisa Mirabello1, Mark Schiffman, Arpita Ghosh, Ana C Rodriguez, Natasa Vasiljevic, Nicolas Wentzensen, Rolando Herrero, Allan Hildesheim, Sholom Wacholder, Dorota Scibior-Bentkowska, Robert D Burk, Attila T Lorincz.   

Abstract

We explored the association of human papillomavirus type 16 (HPV16) DNA methylation with age, viral load, viral persistence and risk of incident and prevalent high grade CIN (CIN2+) in serially collected specimens from the Guanacaste, Costa Rica cohort. 273 exfoliated cervical cell specimens (diagnostic and pre-diagnostic) were selected: (1) 92 with HPV16 DNA clearance (controls), (2) 72 with HPV16 DNA persistence (without CIN2+) and (3) 109 with CIN2+. DNA was extracted, bisulfite converted and methylation was quantified using pyrosequencing assays at 66 CpGs across the HPV genome. The Kruskal-Wallis test was used to determine significant differences among groups, and receiver operating characteristic curve analyses were used to evaluate how well methylation identified women with CIN2+. In diagnostic specimens, 88% of CpG sites had significantly higher methylation levels in CIN2+ after correction for multiple tests compared with controls. The highest area under the ROC curve (AUC) was 0.82 for CpG site 6457 in L1, and a diagnostic sensitivity of 91% corresponded to a specificity of 60% for CIN2+. Prospectively, 17% of CpG sites had significantly higher methylation in pre-diagnostic CIN2+ specimens (median time of 3 years before diagnosis) versus controls. The strongest pre-diagnostic CpG site was 6367 in L1 with an AUC of 0.76. Age-stratified analyses suggested that women older than the median age of 28 years have an increased risk of precancer associated with high methylation. Higher methylation in CIN2+ cases was not explained by higher viral load. We conclude that elevated levels of HPV16 DNA methylation may be useful to predict concurrently diagnosed as well as future CIN2+.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22847263      PMCID: PMC3493709          DOI: 10.1002/ijc.27750

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  Analyzing a portion of the ROC curve.

Authors:  D K McClish
Journal:  Med Decis Making       Date:  1989 Jul-Sep       Impact factor: 2.583

2.  Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project.

Authors:  R Herrero; M H Schiffman; C Bratti; A Hildesheim; I Balmaceda; M E Sherman; M Greenberg; F Cárdenas; V Gómez; K Helgesen; J Morales; M Hutchinson; L Mango; M Alfaro; N W Potischman; S Wacholder; C Swanson; L A Brinton
Journal:  Rev Panam Salud Publica       Date:  1997-05

3.  Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

Authors:  Jennifer S Smith; Lisa Lindsay; Brooke Hoots; Jessica Keys; Silvia Franceschi; Rachel Winer; Gary M Clifford
Journal:  Int J Cancer       Date:  2007-08-01       Impact factor: 7.396

4.  Natural history of cervicovaginal papillomavirus infection in young women.

Authors:  G Y Ho; R Bierman; L Beardsley; C J Chang; R D Burk
Journal:  N Engl J Med       Date:  1998-02-12       Impact factor: 91.245

Review 5.  Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.

Authors:  Marc Arbyn; Peter Sasieni; Chris J L M Meijer; Christine Clavel; George Koliopoulos; Joakim Dillner
Journal:  Vaccine       Date:  2006-08-31       Impact factor: 3.641

6.  CpG methylation of HPV 16 LCR at E2 binding site proximal to P97 is associated with cervical cancer in presence of intact E2.

Authors:  Bornali Bhattacharjee; Sharmila Sengupta
Journal:  Virology       Date:  2006-08-14       Impact factor: 3.616

7.  Human papillomavirus triage for young women with atypical squamous cells of undetermined significance.

Authors:  Jason D Wright; Janet S Rader; Rosa Davila; Matthew A Powell; David G Mutch; Feng Gao; Randall K Gibb
Journal:  Obstet Gynecol       Date:  2006-04       Impact factor: 7.661

8.  CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression.

Authors:  Vinay Badal; Linda S H Chuang; Eileen Hwee-Hong Tan; Sushma Badal; Luisa L Villa; Cosette M Wheeler; Benjamin F L Li; Hans-Ulrich Bernard
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,.

Authors:  M Concepción Bratti; Ana C Rodríguez; Mark Schiffman; Allan Hildesheim; Jorge Morales; Mario Alfaro; Diego Guillén; Martha Hutchinson; Mark E Sherman; Claire Eklund; John Schussler; Julie Buckland; Lidia A Morera; Fernando Cárdenas; Manuel Barrantes; Elmer Pérez; Thomas J Cox; Robert D Burk; Rolando Herrero
Journal:  Rev Panam Salud Publica       Date:  2004-02

10.  Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia.

Authors:  Mina Kalantari; Itzel E Calleja-Macias; Devansu Tewari; Bjørn Hagmar; Kathrine Lie; Hugo A Barrera-Saldana; Dorothy J Wiley; Hans-Ulrich Bernard
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more
  63 in total

1.  Epigenetics of human papillomaviruses.

Authors:  Eric Johannsen; Paul F Lambert
Journal:  Virology       Date:  2013-08-13       Impact factor: 3.616

2.  Disparity in the persistence of high-risk human papillomavirus genotypes between African American and European American women of college age.

Authors:  Carolyn E Banister; Amy R Messersmith; Bo Cai; Lisa B Spiryda; Saundra H Glover; Lucia Pirisi; Kim E Creek
Journal:  J Infect Dis       Date:  2014-07-15       Impact factor: 5.226

3.  HPV16 CpG methyl-haplotypes are associated with cervix precancer and cancer in the Guanacaste natural history study.

Authors:  Marina Frimer; Chang Sun; Thomas McAndrew; Benjamin Smith; Ariana Harari; Zigui Chen; Lisa Mirabello; Nicolas Wentzensen; Gary L Goldberg; Ana C Rodriguez; Mark Schiffman; Robert D Burk
Journal:  Gynecol Oncol       Date:  2015-05-19       Impact factor: 5.482

Review 4.  Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention.

Authors:  Ana Gradíssimo; Robert D Burk
Journal:  Expert Rev Mol Diagn       Date:  2017-02-20       Impact factor: 5.225

5.  Human papillomavirus genomics: past, present and future.

Authors:  Ariana Harari; Zigui Chen; Robert D Burk
Journal:  Curr Probl Dermatol       Date:  2014-03-13

6.  Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women.

Authors:  Megan A Clarke; Ana Gradissimo; Nicolas Wentzensen; Robert D Burk; Mark Schiffman; Jessica Lam; Christopher C Sollecito; Barbara Fetterman; Thomas Lorey; Nancy Poitras; Tina R Raine-Bennett; Philip E Castle
Journal:  Clin Cancer Res       Date:  2018-02-02       Impact factor: 12.531

7.  Folate and vitamin B12 may play a critical role in lowering the HPV 16 methylation-associated risk of developing higher grades of CIN.

Authors:  Chandrika J Piyathilake; Maurizio Macaluso; Michelle M Chambers; Suguna Badiga; Nuzhat R Siddiqui; Walter C Bell; Jeffrey C Edberg; Edward E Partridge; Ronald D Alvarez; Gary L Johanning
Journal:  Cancer Prev Res (Phila)       Date:  2014-08-21

Review 8.  Epigenetic research in cancer epidemiology: trends, opportunities, and challenges.

Authors:  Mukesh Verma; Scott Rogers; Rao L Divi; Sheri D Schully; Stefanie Nelson; L Joseph Su; Sharon A Ross; Susan Pilch; Deborah M Winn; Muin J Khoury
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-12-10       Impact factor: 4.254

Review 9.  Human papillomavirus DNA methylation as a potential biomarker for cervical cancer.

Authors:  Megan A Clarke; Nicolas Wentzensen; Lisa Mirabello; Arpita Ghosh; Sholom Wacholder; Ariana Harari; Attila Lorincz; Mark Schiffman; Robert D Burk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-10-03       Impact factor: 4.254

10.  Filling a gap in cervical cancer screening programmes.

Authors:  Nicolas Wentzensen; Mark Schiffman
Journal:  Lancet Oncol       Date:  2014-02-13       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.